LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

Strona główna・Stock List・Roivant Sciences Ltd

Roivant Sciences Ltd

Closed

SectorHealthcare

28.7 1.85

Buy Sell

Overview

Share price change

24h

Current

Min

28.24

Max

28.78

Key metrics
By Trading Economics
Income	669M 356M
Sales	521K 2.5M
Profit margin	14,116.825
Employees	721
EBITDA	-65M -354M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+30.04% upside

Market Stats
By TradingEconomics
Market Cap	32M 20B
Previous open	26.85
Previous close	28.7

News Sentiment

By Acuity

24%

76%

52 / 344 Ranking in Healthcare

Roivant Sciences Ltd Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

2 cze 2026, 20:30 UTC

Earnings

Palo Alto Networks 3Q Revenue Rises as Customers Beef Up Cyber Defenses

2 cze 2026, 23:58 UTC

Market Talk

Australia's Consumer Sector Expected to Be Stung by Housing Downturn -- Market Talk

2 cze 2026, 23:46 UTC

Market Talk

Global Equities Roundup: Market Talk

2 cze 2026, 23:46 UTC

Market Talk

Nikkei May Rise as AI Demand Hopes Continue -- Market Talk

2 cze 2026, 23:41 UTC

Market Talk

Oil Rises Amid Signs of U.S.-Iran Peace Talks Stalling -- Market Talk

2 cze 2026, 23:01 UTC

Acquisitions, Mergers, Takeovers

ACCC Says Owner of Metro Petroleum Brand to Buy the 41 Sites

2 cze 2026, 23:01 UTC

Acquisitions, Mergers, Takeovers

ACCC Says Ampol Must Sell 41 Retail Fuel Sites to an Approved Purchaser

2 cze 2026, 23:00 UTC

Acquisitions, Mergers, Takeovers

Australia's Competition Regulator Approves Ampol's Purchase of EG Australia With Conditions

2 cze 2026, 22:57 UTC

Market Talk

Australian Dollar Could Fall Following 1Q GDP Data -- Market Talk

2 cze 2026, 22:50 UTC

Market Talk

Ulta Beauty Says TikTok Shop Will Provide 'Halo' Effect -- Market Talk

2 cze 2026, 21:07 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

2 cze 2026, 21:07 UTC

Market Talk

Tokenized Assets Need Access to Digital-Finance Plumbing -- Market Talk

2 cze 2026, 21:00 UTC

Earnings

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2 cze 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

2 cze 2026, 20:46 UTC

Earnings

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2 cze 2026, 20:38 UTC

Earnings

GitLab Stock Rises as the Software Company Raises Guidance on AI Business Momentum -- Barrons.com

2 cze 2026, 20:21 UTC

Earnings

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2 cze 2026, 20:12 UTC

Earnings

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2 cze 2026, 20:05 UTC

Earnings

Palo Alto Networks 3Q Product Rev $594M

2 cze 2026, 20:05 UTC

Earnings

Palo Alto Networks Sees FY26 Next-Generation Security ARR $8.9B-$8.95B

2 cze 2026, 20:05 UTC

Earnings

Palo Alto Networks Raises FY26 View To Adj EPS $3.77-Adj EPS $3.79 >PANW

2 cze 2026, 20:05 UTC

Earnings

Palo Alto Networks 3Q Subscription and Support Rev $2.41B

2 cze 2026, 20:05 UTC

Earnings

Palo Alto Networks Sees FY26 Remaining Performance Obligation $20.9B-$21B

2 cze 2026, 20:05 UTC

Earnings

Palo Alto Networks Sees 4Q Rev $3.345B-$3.355B >PANW

2 cze 2026, 20:05 UTC

Earnings

Palo Alto Networks Sees 4Q Adj EPS 96c-Adj EPS 98c >PANW

2 cze 2026, 20:05 UTC

Earnings

Palo Alto Networks on Track to Achieve 40% Adj Free Cash Flow Margin in FY28

2 cze 2026, 20:05 UTC

Earnings

Palo Alto Networks Raises FY26 View To Rev $11.415B-$11.425B >PANW

2 cze 2026, 20:05 UTC

Earnings

Palo Alto Networks 3Q Remaining Performance Obligation $18.4B

2 cze 2026, 20:05 UTC

Earnings

Palo Alto Networks 3Q Adj EPS 85c >PANW

2 cze 2026, 20:05 UTC

Earnings

Palo Alto Networks 3Q Loss $177M >PANW

Peer Comparison

Price change

Roivant Sciences Ltd Forecast

Price Target

By TipRanks

30.04% upside

12 Months Forecast

Average 37.83 USD 30.04%

High 42 USD

Low 31.5 USD

Based on 9 Wall Street analysts offering 12 month price targets forRoivant Sciences Ltd - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

9 ratings

Buy

Hold

Sell

Based on 9 analysts giving stock ratings to Roivant Sciences Ltd - Dist in the past 3 months.

Sentiment

By Acuity

52 / 344 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Roivant Sciences Ltd

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It offers VTAMA, a novel topical approved for the treatment of psoriasis and in development for the treatment of atopic dermatitis; IMVT-1402 and batoclimab, which are fully human monoclonal antibodies that targets the neonatal Fc receptor in development across various IgG-mediated autoimmune indications; brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis and non-infectious uveitis, as well as for other therapies in various stages of clinical development; and Namilumab, a fully human anti-GM-CSF monoclonal antibody under Phase 2 clinical trial for the treatment of inflammatory and autoimmune diseases. The company also provides delivery platforms comprising lipid nanoparticle platform and ligand conjugate platform. It has collaboration and license agreements with Boehringer Ingelheim International, GmbH for conducting discovery work on RNA-specific adenosine deaminase 1 targeting and modulating compounds; and with Japan Tobacco Inc. for the rights to develop, register, and market tapinarof in Japan for the treatment of psoriasis and atopic dermatitis. The company was founded in 2014 and is based in London, the United Kingdom.